Barclays
ZYME icon

Barclays’s Zymeworks ZYME Stock Holding History

Barclays’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
20,603
+2,229
+12% +$56.6K ﹤0.01% 3174
2026
Q1 		$460K Sell
18,374
-61,592
-77% -$1.46M ﹤0.01% 3236
2025
Q4 		$2.11M Sell
79,966
-119,057
-60% -$2.6M ﹤0.01% 2896
2025
Q3 		$3.4M Buy
199,023
+76,203
+62% +$1.09M ﹤0.01% 2482
2025
Q2 		$1.54M Buy
122,820
+47,390
+63% +$565K ﹤0.01% 3047
2025
Q1 		$898K Sell
75,430
-145,460
-66% -$1.98M ﹤0.01% 3172
2024
Q4 		$3.23M Buy
220,890
+66,506
+43% +$930K ﹤0.01% 2523
2024
Q3 		$1.94M Buy
154,384
+127,595
+476% +$1.39M ﹤0.01% 2872
2024
Q2 		$228K Sell
26,789
-21,515
-45% -$192K ﹤0.01% 3509
2024
Q1 		$508K Sell
48,304
-45,025
-48% -$500K ﹤0.01% 3581
2023
Q4 		$970K Buy
+93,329
New +$744K ﹤0.01% 3454
2023
Q2 		– Sell
-10,900
Closed -$98.5K – 5156
2023
Q1 		$98.5K Buy
+10,900
New +$95.1K ﹤0.01% 4191
2022
Q4 		– Sell
-1,117
Closed -$7K – 5400
2022
Q3 		$7K Hold
1,117
– – ﹤0.01% 4433
2022
Q2 		$6K Sell
1,117
-641
-36% -$3.88K ﹤0.01% 4760
2022
Q1 		$12K Buy
1,758
+641
+57% +$5.71K ﹤0.01% 4572
2021
Q4 		$18K Sell
1,117
-4,769
-81% -$99.4K ﹤0.01% 3957
2021
Q3 		$170K Sell
5,886
-3,672
-38% -$122K ﹤0.01% 3701
2021
Q2 		$332K Sell
9,558
-7,467
-44% -$237K ﹤0.01% 3302
2021
Q1 		$537K Buy
17,025
+15,508
+1,022% +$630K ﹤0.01% 3135
2020
Q4 		$72K Hold
1,517
– – ﹤0.01% 4265
2020
Q3 		$71K Sell
1,517
-82,500
-98% -$2.83M ﹤0.01% 4426
2020
Q2 		$3.03M Buy
+84,017
New +$3.09M ﹤0.01% 1758
2020
Q1 		– Sell
-3,900
Closed -$177K – 6515
2019
Q4 		$177K Hold
3,900
– – ﹤0.01% 5126
2019
Q3 		$97K Hold
3,900
– – ﹤0.01% 5501
2019
Q2 		$86K Buy
+3,900
New +$71.6K ﹤0.01% 5803
2018
Q3 		– Sell
-1,248
Closed -$18K – 7442
2018
Q2 		$18K Buy
+1,248
New +$19.3K ﹤0.01% 6247

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Barclays's ZYME Position: Q2 2026 in Review

Barclays increased its Zymeworks (ZYME) stake by 12% in Q2 2026, buying an estimated $56.6K and bringing the position to 20,603 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #3174.

Barclays first reported a position in ZYME in Q2 2018 and has held it in 26 quarters since. The position peaked at $3.4M in Q3 2025. 202 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

  • Barclays held 20,603 shares of Zymeworks worth $539K as of Q2 2026.
  • Barclays bought 2,229 Zymeworks shares in Q2 2026, an estimated $56.6K.
  • Zymeworks made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3174 holding.
  • Barclays first reported a position in Zymeworks in Q2 2018 and has held it in 26 quarters since.
  • Barclays's Zymeworks position peaked at $3.4M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.